Streamlining Medicaid Ajovy Prior Authorization

Understanding Ajovy and Medicaid PA Dynamics

Ajovy, a CGRP inhibitor, represents a significant treatment option for chronic migraine prevention, often requiring prior authorization across all payer types, including Medicaid. The Medicaid program itself operates through two primary models: Fee-for-Service (FFS), where state Medicaid agencies directly manage benefits, and Medicaid Managed Care, where states contract with MCOs (such as Centene subsidiaries, Molina, UHC Community Plan, or Anthem Medicaid plans) to administer care. This dual structure means prior authorization requirements for specialty drugs like Ajovy can vary significantly not only between states but also among MCOs within the same state.

Medicaid Prior Authorization Channels and Complexity

The channels for submitting Medicaid prior authorizations are as diverse as the program's structure. For FFS Medicaid, submissions typically route through a state Medicaid agency's fiscal agent or a dedicated state Medicaid portal. Conversely, for managed care members, prior authorizations must be submitted via the responsible MCO's provider portal. While X12 278 electronic prior authorization routing offers a more standardized approach, its support varies by state and MCO. This fragmented landscape necessitates a flexible and adaptable submission strategy for high-volume specialty drugs like Ajovy.

Key Considerations for Specialty Drug PA in Medicaid

• **State-Specific Medical Necessity Criteria:** Each state Medicaid agency publishes its own medical necessity criteria, which MCOs generally cannot make more restrictive.
• **Formulary and Step Therapy:** Many Medicaid plans, both FFS and MCO, implement formulary tiers and step therapy protocols for specialty drugs, requiring patients to try alternative, often lower-cost, therapies first.
• **Quantity Limits:** To manage costs and ensure appropriate utilization, quantity limits are common for specialty medications like Ajovy.
• **Documentation Requirements:** Comprehensive clinical documentation supporting the diagnosis, previous treatments, and medical necessity is crucial for approval.
• **Dual-Eligible Coordination:** For patients with both Medicare and Medicaid (D-SNP), careful coordination of benefits and PA requirements between the two programs is essential.

Navigating Policy and Regulatory Landscape

Medicaid managed care organizations are directly impacted by federal regulations such as CMS-0057-F, which mandates specific prior authorization decision timeframes (72-hour standard, 24-hour expedited) and requires the implementation of FHIR-based Prior Authorization APIs on a phased timeline. While traditional FFS Medicaid is less directly impacted by the API requirements, the broader push for interoperability affects the entire Medicaid ecosystem. Accessing current medical necessity criteria is paramount, typically found in state Medicaid agency policy libraries, with the CMS Medicare Coverage Database providing additional insights for dual-eligibles.

Klivira's Approach to Medicaid Ajovy PA Automation

Klivira’s platform is engineered to navigate the intricate landscape of Medicaid prior authorization for specialty drugs like Ajovy. Our system intelligently identifies the responsible delivery model (FFS or managed care) and, if managed care, the specific MCO. We integrate with diverse submission channels, including state Medicaid portals, MCO provider portals, and X12 278 routing where available. By leveraging state Medicaid agency rules as the foundational criteria and coordinating D-SNP requirements, Klivira automates the submission process, significantly reducing manual effort and accelerating approval times for Ajovy.